News | November 25, 2025
Eris Lifesciences consolidates its stake in Swiss Parenterals
The proposed transaction will be effected as a share swap
The proposed transaction will be effected as a share swap
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
The non-dilutive financing includes three tranches
Millions of stroke survivors across the world may soon have a new defense
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Desai is currently serving the company as Group Finance Controller
Winlevi is authorized in EU for the treatment of acne vulgaris
Subscribe To Our Newsletter & Stay Updated
